| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.029 | 0.9 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | ABT-263 | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |